Termination of antigen-specific immunity by CD95 ligand (fas ligand) and IL-10

Journal of Immunology

Volumn 173, Issue 3, 2004, Pages 1519-1525

  Barreiro, Ramon ^a   Luker, Gary ^a   Herndon, John ^a   Ferguson, Thomas A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOREACTIVITY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN;

EID: 3242776818     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.3.1519     Document Type: Article

References (37)

1. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
2. Brunner, T., N. J. Yoo, D. LaFace, C. F. Ware, and D. R. Green. 1996. Activation-induced cell death in murine T cell hybridomas: differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int. Immunol. 8:1017.
3. Pinkoski, M. J., N. M. Droin, T. Lin, L. Genestier, T. A. Ferguson, and D. R. Green. 2002. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc. Natl. Acad. Sci. USA 99:16174.
4. Bonfoco, E., P. M. Stuart, T. Brunner, T. Lin, T. S. Griffith, Y. Gao, H. Nakajima, P. A. Henkart, T. A. Ferguson, and D. R. Green. 1998. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9:711.
5. Griffith, T. S., X. Yu, J. M. Herndon, D. R. Green, and T. A. Ferguson. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7.
6. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189.
7. Hu, M. S., J. D. Schwartzman, G. R. Yeaman, J. Collins, R. Seguin, I. A. Khan, and L. H. Kasper. 1999. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect. Immun. 67:928.
8. Giordano, C., G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi, and A. Galluzzo. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960.
9. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
10. O'Connell, J., M. W. Bennett, K. Nally, A. Houston, G. C. O'Sullivan, and F. Shanahan. 2000. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann. NY Acad. Sci. 910:178.
11. Schwarz, A., S. Grabbe, K. Grosse-Heitmeyer, B. Roters, H. Riemann, T. A. Luger, G. Trinchieri, and T. Schwarz. 1998. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system. J. Immunol. 160:4262.
12. + T cells produce active immune unresponsiveness. J. Immunol. 168:5589.
13. Flugel, A., F. W. Schwaiger, H. Neumann, I. Medana, M. Willem, H. Wekerle, G. W. Kreutzberg, and M. B. Graeber. 2000. Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol. 10:353.
14. D'Alessio, A., A. Riccioli, P. Lauretti, F. Padula, B. Muciaccia, P. De Cesaris, A. Filippini, S. Nagata, and E. Ziparo. 2001. Testicular FasL is expressed by sperm cells. Proc. Natl. Acad. Sci. USA 98:3316.
15. Li, X. K., T. Okuyama, A. Tamura, S. Enosawa, Y. Kaneda, S. Takahara, N. Funashima, M. Yamada, H. Amemiya, and S. Suzuki. 1998. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 66:1416.
16. Swenson, K. M., B. Ke, T. Wang, J. S. Markowitz, M. A. Maggard, G. S. Spear, D. K. Imagawa, J. A. Goss, R. W. Busuttil, and P. Seu. 1998. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65:155.
17. Takeuchi, T., T. Ueki, H. Nishimatsu, T. Kajiwara, T. Ishida, K. Jishage, O. Ueda, H. Suzuki, B. Li, N. Moriyama, and T. Kitamura. 1999. Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162:518.
18. Hill, L. L., V. K. Shreedhar, M. L. Kripke, and L. B. Owen-Schaub. 1999. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J. Exp. Med. 189:1285.
19. Hill, L. L., A. Ouhtit, S. M. Loughlin, M. L. Kripke, H. N. Ananthaswamy, and L. B. Owen-Schaub. 1999. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 285:898.
20. Arnold, R., M. Seifert, K. Asadullah, and H. D. Volk. 1999. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J. Immunol. 162:7140.
21. Berthou, C., L. Michel, A. Soulie, F. Jean-Louis, B. Flageul, L. Dubertret, F. Sigaux, Y. Zhang, and M. Sasportes. 1997. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J. Immunol. 159:5293.
22. Shibaki, A., and S. I. Katz. 2001. Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. Eur. J. Immunol. 31:3006.
23. Nagata, S. 1999. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33:29.
24. Johnsen, A. C., J. Haux, B. Steinkjer, U. Nonstad, K. Egeberg, A. Sundan, A. Ashkenazi, and T. Espevik. 1999. Regulation of APO-2 ligand/TRAIL expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 11:664.
25. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683.
26. Ferguson, T. A., P. Dube, and T. S. Griffith. 1994. Regulation of contact hypersensitivity by interleukin 10. J. Exp. Med. 179:1597.
27. -/- mice: an overview. J. Leukocyte Biol. 61:389.
28. Barreiro, R., R. Schadlu, J. Herndon, H. J. Kaplan, and T. A. Ferguson. 2003. The role of Fas-FasL in the development and treatment of ischemic retinopathy. Invest. Ophthalmol. Vis. Sci. 44:1282.
29. Norian, L. A., K. M. Latinis, S. L. Eliason, K. Lyson, C. Yang, T. Ratliff, and G. A. Koretzky. 2000. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice. J. Immunol. 164:4471.
30. Luker, G. D., J. P. Bardill, J. L. Prior, C. M. Pica, D. Piwnica-Worms, and D. A. Leib. 2002. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 76:12149.
31. Ferguson, T. A., and D. R. Green. 2001. Fas-ligand and immune privilege: the eyes have it. Cell Death Differ. 8:771.
32. Ferguson, T. A., and T. S. Griffith. 1997. A vision of cell death: insights into immune privilege. Immunol. Rev. 156:167.
33. Gutierrez-Steil, C., T. Wrone-Smith, X. Sun, J. G. Krueger, T. Coven, and B. J. Nickoloff. 1998. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J. Clin. Invest. 101:33.
34. Rivas, J. M., and S. E. Ullrich. 1992. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes: an essential role for keratinocyte-derived IL-10. J. Immunol. 149:3865.
35. Schmidt, M., N. Lugering, H. G. Pauels, K. Schulze-Osthoff, W. Domschke, and T. Kucharzik. 2000. IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway. Eur. J. Immunol. 30:1769.
36. Georgescu, L., R. K. Vakkalanka, K. B. Elkon, and M. K. Crow. 1997. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J. Clin. Invest. 100:2622.
37. Saito, I., K. Haruta, M. Shimuta, H. Inoue, H. Sakurai, K. Yamada, N. Ishimaru, H. Higashiyama, T. Sumida, H. Ishida, et al. 1999. Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10. J. Immunol. 162:2488.